Continuing Medical Education
Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 19.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (cme) credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by December 3, 2024. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 19.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
The field of cancer immunotherapy represents a revolutionary approach in cancer research, harnessing the body’s immune system to combat cancer with greater safety and tolerance compared to traditional treatments like chemotherapy and radiation. This innovative strategy has led to numerous breakthroughs, including monoclonal antibodies, checkpoint inhibitors, adoptive cell transfer, therapeutic vaccines, cytokines, and oncolytic viruses, transforming the landscape of cancer treatment.
However, despite these remarkable advancements, challenges persist in targeting solid tumors effectively with adoptive cell therapies. Additionally, ongoing research is focused on understanding and mitigating immunotherapy-related toxicity and resistance. Exciting developments in next-generation treatments, novel checkpoints, and neoadjuvant therapies are being explored, alongside the use of complex computational models to delve deeper into the immune microenvironment, thus paving the way for more efficacious treatments.
This conference serves as a platform for collaboration and knowledge exchange among leading oncologists, physician-scientists, and immunologists at the forefront of immunologic breakthroughs in cancer treatment. The program encompasses a wide range of cutting-edge topics, including adoptive cell therapy, artificial intelligence, metabolism, the microbiome, and emerging technologies, among others. These discussions aim to deepen our understanding of the immune response to cancer, ultimately driving the development of more effective and personalized therapies.
The immune system’s ability to identify and eliminate cancer cells mirrors its response to pathogens like bacteria and viruses. However, cancer cells can evade immune surveillance mechanisms, leading to tumor growth and progression. Immunotherapies leverage this knowledge to enhance the immune system’s ability to target cancer cells. Despite significant progress, immunotherapies are not universally effective across all patients and cancer types, and challenges exist in scaling up cell-based therapies for widespread clinical use.
Physician-scientists and practicing oncologists attending this conference will gain valuable insights into the complexities of cancer immunology and pending therapeutic advancements. By fostering collaboration between basic scientists, translational researchers, and clinicians, this event aims to accelerate the translation of fundamental immunological science into innovative treatments that can benefit cancer patients worldwide
After participating in this CME activity, physicians should be able to:
- Explain the impact of tumor evolution and tumor microenvironment on the immune system and current immunotherapies.
- Differentiate the roles of Myeloid/NK and other immune cells and their potential for clinical impact.
- Assess the impact of new checkpoints and combinations. Assess the clinical progress of vaccines as a therapeutic modality.
- Identify recent advances in T cell engineering and Cellular Therapy.
- Provide recent insights into immunometabolism, the microbiome, and emerging technologies.
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.
Acknowledgment of Financial or Other Support
The AACR gratefully acknowledges the following commercial supporters for their Professional Educational Grants:
- Novartis
- Pfizer
questions about cme?
Please read our frequently asked questions. If you still have questions, contact the Office of CME at (215) 440-9300 or [email protected].